US20230051702A1 - Compositions for prevention and treatment of symptoms associated with alcohol consumption - Google Patents
Compositions for prevention and treatment of symptoms associated with alcohol consumption Download PDFInfo
- Publication number
- US20230051702A1 US20230051702A1 US17/977,969 US202217977969A US2023051702A1 US 20230051702 A1 US20230051702 A1 US 20230051702A1 US 202217977969 A US202217977969 A US 202217977969A US 2023051702 A1 US2023051702 A1 US 2023051702A1
- Authority
- US
- United States
- Prior art keywords
- composition
- veisalgia
- treatment
- alcohol
- integrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 208000024891 symptom Diseases 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title description 44
- 230000002265 prevention Effects 0.000 title description 4
- 239000004615 ingredient Substances 0.000 claims abstract description 23
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 18
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims abstract description 16
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims abstract description 16
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 16
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims abstract description 16
- 229940120668 salicin Drugs 0.000 claims abstract description 16
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 15
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108010004032 Bromelains Proteins 0.000 claims abstract description 11
- 240000001439 Opuntia Species 0.000 claims abstract description 11
- 239000004365 Protease Substances 0.000 claims abstract description 11
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 11
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019835 bromelain Nutrition 0.000 claims abstract description 11
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000005875 quercetin Nutrition 0.000 claims abstract description 11
- 229960001285 quercetin Drugs 0.000 claims abstract description 11
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 9
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241001409321 Siraitia grosvenorii Species 0.000 claims abstract description 9
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 9
- 239000011777 magnesium Substances 0.000 claims abstract description 9
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 9
- 235000001055 magnesium Nutrition 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 235000013976 turmeric Nutrition 0.000 claims abstract description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001948 caffeine Drugs 0.000 claims abstract description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000012754 curcumin Nutrition 0.000 claims abstract description 8
- 239000004148 curcumin Substances 0.000 claims abstract description 8
- 229940109262 curcumin Drugs 0.000 claims abstract description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 8
- 239000011591 potassium Substances 0.000 claims abstract description 8
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 8
- 235000007686 potassium Nutrition 0.000 claims abstract description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 7
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 7
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011734 sodium Substances 0.000 claims abstract description 7
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 7
- 235000015424 sodium Nutrition 0.000 claims abstract description 7
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 7
- 239000011720 vitamin B Substances 0.000 claims abstract description 7
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 7
- 239000011718 vitamin C Substances 0.000 claims abstract description 7
- 235000020744 piper nigrum extract Nutrition 0.000 claims abstract description 6
- 229960003080 taurine Drugs 0.000 claims abstract description 6
- 229940102465 ginger root Drugs 0.000 claims abstract description 5
- 239000001841 zingiber officinale Substances 0.000 claims abstract description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 8
- 241000320380 Silybum Species 0.000 claims description 7
- 235000010841 Silybum marianum Nutrition 0.000 claims description 7
- 229940023488 pill Drugs 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 6
- 239000007910 chewable tablet Substances 0.000 claims description 5
- 229940068682 chewable tablet Drugs 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002663 nebulization Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 3
- 230000000116 mitigating effect Effects 0.000 abstract description 3
- 206010019133 Hangover Diseases 0.000 description 31
- 206010019233 Headaches Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000124033 Salix Species 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
- 241000219357 Cactaceae Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 244000010000 Hovenia dulcis Species 0.000 description 2
- 235000008584 Hovenia dulcis Nutrition 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 235000004727 Opuntia ficus indica Nutrition 0.000 description 2
- 240000009297 Opuntia ficus-indica Species 0.000 description 2
- 241000219000 Populus Species 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 230000001739 rebound effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- YQIFAMYNGGOTFB-NJGYIYPDSA-N 7,8-dihydromonapterin Chemical compound N1CC([C@H](O)[C@@H](O)CO)=NC2=C1N=C(N)NC2=O YQIFAMYNGGOTFB-NJGYIYPDSA-N 0.000 description 1
- AUNGANRZJHBGPY-MBNYWOFBSA-N 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-MBNYWOFBSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 241001090476 Castoreum Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000008607 Opuntia megacantha Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000002454 curcuma longa l. root extract Substances 0.000 description 1
- 235000020241 curcumin extract Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Definitions
- the present invention relates to the pharmacological treatment of veisalgia and, specifically, compositions for prevention, mitigation, and treatment of symptoms associated with alcohol consumption.
- acetaldehyde is created as a byproduct.
- Acetaldehyde can be 10 to 30 times more toxic to humans than alcohol itself.
- the body reacts to the acetaldehyde, causing immune system responses by the body trying to defend itself from the toxic byproduct.
- various parts of the body become inflamed, including the skin, liver, pancreas, eyes, etc. This inflammation hinders or prevents the body from absorbing liquid, thereby preventing the body from improving the alcohol-induced dehydration.
- Alcohol can enter the brain within minutes of consumption. Initially, alcohol causes the consumer to feel drowsy when intoxicated. Alcohol mimics gamma-aminobutyric acid (“GABA”), the major inhibitory neurotransmitter in the brain. When bound to GABA receptors on a neuron, alcohol allows either the influx of negative (or efflux of positive) ions, giving the cell a more negative charge. Thus, the neuron's ability to fire is diminished.
- GABA gamma-aminobutyric acid
- NMDA N-methyl-D-aspartate
- NSAIDs nonsteroidal anti-inflammatory drugs
- aspirin and ibuprofen are used.
- NSAIDs are generally effective at relieving headaches and muscle aches.
- NSAIDs also cause intestinal irritability while not addressing other hangover symptoms including certain inflammation caused by alcohol consumption that cannot be treated with nSAIDs
- Vitamins are also used to combat hangover symptoms. Alcohol depletes some water-soluble vitamins, especially B complex vitamins. However, vitamin supplementation after the onset of a hangover will have little to no effect on the hangover following acute alcohol consumption. Moreover, there is little to no evidence that vitamin supplements alone improve acute hangover symptoms.
- NAC N-acetylcysteine or N-Acetyl L-Cysteine
- Caffeine is a commonly used stimulant to combat the lethargy and headaches associated with hangovers.
- many caffeinated drinks such as coffee are diuretics and can exacerbate the dehydration associated with the hangover.
- hangovers are a form of alcohol withdrawal and drinking more alcohol will ease the withdrawal. However, this perpetuates the cycle of drinking, ultimately prolonging the hangover, and can lead to addiction.
- hangover remedies A common problem to most currently available hangover remedies is that the antidotes are applied typically when the hangover symptoms have already commenced, i.e. the critical period to prevent and/or treat adverse symptoms have progressed too long to be efficacious. Further, most commercially-available hangover remedies fail to address inflammation effects of alcohol toxicity by specifically using anti-inflammatory agents. Typically, hangover symptoms peak when the blood alcohol content (“BAC”) is near or at zero. Therefore, what is needed is a hangover treatment that contains compositions that mitigate symptoms associated with veisalgia and that enable the body to prevent a hangover from setting in. This need has heretofore remained unsatisfied.
- the present invention overcomes these and other deficiencies of the prior art by providing a composition for veisalgia treatment that mitigates and prevents its symptoms.
- a composition stimulates enzymes associated with metabolizing alcohol and/or acetaldehyde—both toxic substances—into acetate—a non-toxic substance.
- the composition is directed to stimulating alcohol dehydrogenases (“ADH”)— a group of dehydrogenase enzymes that occur in many organisms and facilitate the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (“NAD”) to NADH.
- ADH serves to break down alcohols that otherwise are toxic, and they also participate in generation of useful aldehyde, ketone, or alcohol groups during biosynthesis of various metabolites.
- the present invention stimulates the body's production of aldehyde dehydrogenases (“ALDH”)—a group of enzymes that catalyze the oxidation of aldehydes.
- ALDH converts aldehydes to carboxylic acids.
- a composition for treating symptoms associated with veisalgia comprises dihydromyricetin, N-acetyl cysteine, and salicin.
- the composition further comprises at least one of the ingredients selected from the group consisting of: quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, turmeric, curcumin, milk thistle, monk fruit, hydroxypropyl-beta cyclodextrin, ginger root, and black pepper extract.
- the composition is integrated into a liquid.
- the composition is integrated into a capsule, tablet, chewable tablet, or pill.
- the composition is a powder or liquid form and is readily integratable into food or drink.
- a method for treating symptoms associated with veisalgia comprises administering, to a patient, a composition comprising dihydromyricetin, N-acetyl cysteine, and salicin.
- the composition further comprises quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, turmeric, curcumin, milk thistle, monk fruit, hydroxypropyl-beta cyclodextrin, ginger root, or black pepper extract, or a combination thereof.
- the composition is administered as a liquid.
- the composition is administered as a capsule, tablet, chewable tablet, or pill.
- the composition is administered via food or drink.
- the composition is administered by injection intravenously, intramuscularly, intrathecally, or subcutaneously; sublingually or buccally; rectally or vaginally; placed in the eye by the ocular route or the ear by the otic route; nasally; inhalation or by nebulization; applied to the skin cutaneous for a local topical or body wide systemic effect; or delivered through the skin by patch transdermally for systemic effect.
- FIG. 1 illustrates a table of exemplary amounts of ingredients, all various subsets of which are found in one or more embodiments of the present invention.
- FIG. 2 illustrates exemplary methods of administering a composition for treating veisalgia.
- FIGS. 1 - 2 Preferred embodiments of the present invention and their advantages may be understood by referring to FIGS. 1 - 2 . Further features and advantages of the invention, as well as the structure and operation of various embodiments of the invention, are described in detail below. Although the invention is described in the context of a compound, any form may be implemented such as, but not limited to a powder, a pill, or a liquid, or other form suitable for various administrations, including as a nutritional supplement to treat other maladies such as headaches, dehydration, fatigue, and sensitivity to light and sound.
- a composition for veisalgia treatment comprises dihydromyricetin (“DHM”).
- DHM is used as an alcohol metabolism accelerator.
- DHM may be found naturally in the Japanese raisin tree ( Hovenia dulcis ) and has been used in Chinese herbal tea.
- DHM may also be referred to as ampelopsin and found in vine tea extract.
- DHM accelerates alcohol metabolism but it can also prevent alcohol from affecting the brain's GABA receptors, thereby mitigating or preventing the rebound effect.
- the composition for veisalgia treatment may further comprise Salicin. Salicin is commonly found in Willow Bark and may be utilized in various concentrations.
- some embodiments comprise Willow Bark having 15% to 98% concentration of salicin.
- Salicin is an alcoholic beta-glucoside and is produced in willow (salix) bark and has anti-inflammatory properties. Salicin is also commonly found in the bark of populus species, and the leaves of willows and poplars. It may also be found in castoreum, which may be used as an analgesic, anti-inflammatory, and antipyretic.
- the composition for veisalgia treatment may further comprise NAC.
- a composition for veisalgia treatment may further comprise quercetin—a chemical found naturally in a number of foods and in some herbs. It acts as an antioxidant and also possesses anti-inflammatory and antihistamine properties, which reduces inflammation and allergic reactions triggered by alcohol.
- quercetin a chemical found naturally in a number of foods and in some herbs. It acts as an antioxidant and also possesses anti-inflammatory and antihistamine properties, which reduces inflammation and allergic reactions triggered by alcohol.
- Other embodiments include bromelain, which supports normal mucosal tissue function and enhances the absorption of quercetin. Some embodiments include a combination of quercetin and bromelain, while other embodiments may include the combination of quercetin and bromelain in leu of salicin.
- a composition for treating veisalgia mitigates adverse alcohol effects in the body by accelerating alcohol metabolism in the liver and supporting the immune system.
- a composition for treating veisalgia functions as an alcohol metabolism accelerator and as a natural anti-inflammatory.
- the dual benefit contributes to positive effects on headache and fatigue post-alcohol overconsumption.
- a composition for treating veisalgia comprises at least one anti-inflammatory agent that attenuates headaches or muscle aches associated with veisalgia.
- the at least one anti-inflammatory agent is one selected form a group including: salicin (willow bark), Quercetin, Bromelain, or a combination thereof.
- a composition for veisalgia treatment comprises an extract of Opuntia ficus - indica.
- Opuntia ficus - indica is commonly referred to as prickly pear and is a genus in the cactus family, Cactaceae.
- Various forms of Opuntia may be used.
- some embodiments of the present invention comprise the extract Tex-OE® which includes special active molecules derived from the skin of the fruit of the Prickly Pear.
- Some embodiments include cactus extract at a concentration of 4:1.
- a composition for veisalgia treatment comprises caffeine.
- a composition for veisalgia treatment comprises turmeric. Some embodiments comprise turmeric root extract. Other embodiments comprise curcumin extract. Curcumin is a natural anti-inflammatory and many of the adverse effects of alcohol hangovers are due to inflammation.
- a composition for veisalgia treatment comprises approximately 200 mg to 1000 mg of curcumin and/or turmeric. Some embodiments include turmeric comprising approximately 10% curcumin.
- a composition for veisalgia treatment comprises Monk Fruit, which has anti-inflammatory properties and is safe for diabetes in that there are no calories, carbs, sugar, or fat.
- a composition for veisalgia treatment comprises approximately 5 mg to 200 mg of Monk Fruit. Some embodiments include Monk Fruit MV 50%.
- a composition for veisalgia treatment comprises Milk Thistle, which supports liver health.
- a composition for veisalgia treatment comprises approximately 5 mg to 200 mg of Milk Thistle.
- Some embodiments include Milk Thistle comprising approximately 80% silymarin.
- a composition for veisalgia treatment comprises hydroxypropyl-beta cyclodextrin (“HPBCD”), a highly soluble substance which can be used to increase the solubility of the ingredients.
- HPBCD may be used, for example, in integrating the composition for veisalgia treatment into a liquid form. Additionally, HPBCD may be used to enhance the absorption rate of the composition for treating veisalgia.
- a composition for veisalgia treatment comprises approximately 3 g to 8 g of HPBCD.
- a composition for veisalgia treatment comprises ginger.
- Some embodiments comprise ginger root extract while others comprise powdered ginger.
- a composition for veisalgia treatment comprises taurine.
- Other embodiments comprise black pepper extract.
- a composition for veisalgia treatment comprises potassium, sodium, and/or magnesium, either individually or in combination.
- Alcohol like any diuretic, depletes the body of potassium and salts.
- these minerals in this composition is necessary for body rehydration and proper nerve and muscle functions.
- magnesium may support the alcohol dehydrogenase (“ADH”), an enzyme in accelerating the alcohol break down and eliminating it from the body.
- ADH alcohol dehydrogenase
- Some embodiments include magnesium comprising approximately 60% oxide.
- a composition for veisalgia treatment comprises various B vitamins, including but not limited to, thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), biotin (B7), folic acid, vitamin B6, and/or vitamin B12.
- B vitamins including but not limited to, thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), biotin (B7), folic acid, vitamin B6, and/or vitamin B12.
- B1 thiamine
- riboflavin B2
- niacin B3
- pantothenic acid B5
- biotin B7
- folic acid vitamin B6, and/or vitamin B12.
- Some embodiments comprise thiamine HCL, riboflavin 5-phosphate, and/or pyridoxine HCL.
- a composition for veisalgia treatment comprises vitamin C.
- Some embodiments include vitamin C comprising calcium ascorbate.
- a composition for veisalgia treatment is a compound comprising a combination of DHM, willow bark (salicin), N-acetyl cysteine (“NAC”), opuntia (nopal cactus), quercetin, and/or bromelain.
- a composition for veisalgia treatment is a beverage comprising DHM, willow bark, NAC, opuntia, a combination of B vitamins, potassium, sodium, magnesium, quercetin, and/or bromelain.
- the table depicted in FIG. 1 illustrates some of the ingredients of the present invention, along with exemplary amounts for each. Notably, the table is not offered as an exhaustive or exclusive list but rather as exemplary ingredients. Moreover, the ingredients may be used by themselves, in combination with some or all of the other ingredients listed, or with other ingredients not listed, without departing from the embodiments contemplated herein. Further, the ingredients listed may be incorporated in various concentrations. For example, willow bark includes salicin in varying concentrations. Willow bark may have salicin concentrations of anywhere between approximately 15% to approximately 98%—the entire range of which may be used in amount varying between approximately 40 mg to approximately 180 mg.
- the ingredients listed may be utilized in treatments for veisalgia outside of the amounts shown without departing from the embodiments contemplated herein.
- other ingredients may be used to assist administration.
- HPBCD is used to make a homogenous liquid by improving the water solubility of the ingredients.
- the veisalgia treatment may further include natural and/or artificial flavorings or colors.
- the natural flavorings include monk fruit.
- the veisalgia treatment may also include binding agents or other inactive ingredients.
- a composition for veisalgia treatment 200 may be administered in a variety of ways at step 210 .
- the veisalgia treatment 200 comprises composition according to the embodiments described above.
- the veisalgia treatment 200 may be administered by injection including intravenously, intramuscularly, intrathecally, or subcutaneously.
- the veisalgia treatment 200 may be administered sublingually or buccally.
- the veisalgia treatment 200 may be administered rectally or vaginally.
- the veisalgia treatment 200 may be administered ocularly (through the eye) or oticly (through the ear). In another embodiment, as shown at step 260 , the veisalgia treatment 200 may be administered nasally by, for example, through inhalation or by nebulization. In another embodiment, as shown at step 270 , the veisalgia treatment 200 may be administered topically or transdermally, for example by patch.
- the present invention may discuss a composition for veisalgia treatment in the form of a compound, other forms may be utilized without departing from the embodiments contemplated herein.
- the present invention may be administered orally.
- the veisalgia treatment may be integrated into a liquid, capsule, tablet, chewable tablet, or pill.
- a liquid veisalgia treatment may be prepared by first combining HPBCD, DHM, Salicin, NAC, and Turmeric (as exemplary ingredients). Next, the remaining ingredients (such as flavoring compounds), if any, may be separately combined. The two mixtures may then be combined to finalize the liquid veisalgia treatment.
- Some embodiments further include flavorings.
- various embodiments comprise natural flavorings including lemon and lime flavorings.
- Other embodiments may include citric acid and/or malic acid.
- a composition for veisalgia treatment may be integrated into food by, for example, being included in the food's preparation, e.g., added as an ingredient into a food such as candy/protein/power bar or mixed in yogurt, or may be integrated into food in the way many condiments are, e.g., a powder or liquid form that is sprinkled on or added into food much like salt, pepper, ketchup, or mustard.
- the veisalgia treatment may be integrated into the drinker's alcoholic beverage, either being mixed into the alcohol itself or added by the consumer/preparer of the beverage. An advantage to this embodiment is the drinker may ensure the veisalgia treatment is indeed administered and/or administered in the proper amount.
- the present invention may also be administered to a patient in other ways without departing from the embodiments contemplated herein including: given by injection into a vein (intravenously, IV), into a muscle (intramuscularly, IM), into the space around the spinal cord (intrathecally), or beneath the skin (subcutaneously, SC); placed under the tongue (sublingually) or between the gums and cheek (buccally); inserted in the rectum (rectally) or vagina (vaginally); placed in the eye (by the ocular route) or the ear (by the otic route); sprayed into the nose and absorbed through the nasal membranes (nasally); breathed into the lungs, usually through the mouth (by inhalation) or mouth and nose (by nebulization); applied to the skin (cutaneously) for a local (topical) or bodywide (systemic) effect; and/or delivered through the skin by patch (transdermally) for systemic effect.
- the present invention is described herein as a composition for treating veisalgia, the invention may be used to treat other maladies, including, for example, dehydration, nausea, fatigue, headache, light and sound sensitivity, and dizziness.
- the present invention may also be used to treat patients with migraine headaches. Migraine patients reported that the presently described veisalgia treatment helped them (on more than one occasion) to cope with alcohol-triggered migraines. After taking the presently described veisalgia treatment, patients reported a “surprisingly positive” experience of waking up with no migraine or headache triggered by alcohol overconsumption.
- the present invention is shown and described as comprising various specific ingredients, the present invention may include all subsets of disclosed ingredients, without departing from the embodiments contemplated herein.
- the composition for treatment of veisalgia may be administered in capsule form.
- the ingredients are mixed together until homogenous.
- Various types of encapsulation may be utilized, for example, single-piece gel encapsulation (soft capsules) and two-piece gel encapsulation (hard capsules).
- the ingredients may be suspended in a liquid (such as oil) and placed inside of the capsule.
- the composition for treatment of veisalgia may be offered in liquid form.
- the specified ingredients may be homogenously mixed together and dissolved in a medium.
Abstract
A composition for mitigating, treating, and/or preventing symptoms associated with veisalgia. In one embodiment the composition comprises one or more ingredients selected from the group consisting of: dihydromyricetin, N-acetyl cysteine, salicin, quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, monk fruit, turmeric, curcumin, ginger root, and black pepper extract. A method for treating symptoms associated with veisalgia is also described. In one embodiment, the composition is administered in liquid or pill form.
Description
- The present application is a continuation of, and claims priority to, U.S. Non-Provisional patent application Ser. No. 16/799,792 filed on Feb. 24, 2020, entitled “COMPOSITIONS FOR PREVENTION AND TREATMENT OF SYMPTOMS ASSOCIATED WITH ALCOHOL CONSUMPTION,” which claims priority to U.S. Provisional Patent Application No. 62/809,497 filed on Feb. 22, 2019, entitled “COMPOSITIONS FOR PREVENTION AND TREATMENT OF SYMPTOMS ASSOCIATED WITH ALCOHOL CONSUMPTION,” the entire disclosures of which are incorporated by reference herein.
- The present invention relates to the pharmacological treatment of veisalgia and, specifically, compositions for prevention, mitigation, and treatment of symptoms associated with alcohol consumption.
- For thousands of years, humans have been making and consuming alcohol and have also been, presumably, over-consuming alcohol for thousands of years. Some studies have found evidence of intentionally fermented beverages that existed as early as the Neolithic period, some 12,000 years ago. Today, purposeful production and consumption of alcoholic beverages is common and often reflects cultural and/or religious peculiarities as much as geographical and sociological environments.
- While consuming alcohol can give a desirable euphoric effect, it can also give a consumer a number of negative physiological and/or psychological side effects. For example, a consumer may experience headache, drowsiness, concentration problems, dry mouth, dizziness, fatigue, gastrointestinal distress (e.g., vomiting), absence of hunger, depression, sweating, nausea, hyper-excitability, and anxiety, among other symptoms. These symptoms are medically referred to as “veisalgia” and commonly referred to as a “hangover.” Hangovers are generally attributed to a combination of dehydration and toxicity from impurities found in alcohol (congeners). These symptoms may be particularly severe, especially after heavy consumption of alcohol.
- Some aspects of alcohol's negative effect on the body start when alcohol is digested and broken down. When the body breaks down alcohol, acetaldehyde is created as a byproduct. Acetaldehyde can be 10 to 30 times more toxic to humans than alcohol itself. Once present, the body reacts to the acetaldehyde, causing immune system responses by the body trying to defend itself from the toxic byproduct. As a result, various parts of the body become inflamed, including the skin, liver, pancreas, eyes, etc. This inflammation hinders or prevents the body from absorbing liquid, thereby preventing the body from improving the alcohol-induced dehydration.
- Although veisalgia is generally not life-threatening, it may be extremely unpleasant and prevents the afflicted from performing at a typical level. Some studies estimate that 25% of college students have experienced a hangover within the previous seven days and 29% reported losing classroom time due to a hangover. Other studies estimate that excessive drinking costs the United States economy around $220B annually—approximately $1.90 per drink consumed in the United States.
- Consuming alcohol may also adversely affect one's sleeping patterns. Alcohol can enter the brain within minutes of consumption. Initially, alcohol causes the consumer to feel drowsy when intoxicated. Alcohol mimics gamma-aminobutyric acid (“GABA”), the major inhibitory neurotransmitter in the brain. When bound to GABA receptors on a neuron, alcohol allows either the influx of negative (or efflux of positive) ions, giving the cell a more negative charge. Thus, the neuron's ability to fire is diminished. Similarly, alcohol also inhibits the brain's major excitatory neurotransmitter, glutamate, by blocking its function through N-methyl-D-aspartate (“NMDA”) receptors binding (and similar effects through inhibited acetylcholine and serotonin receptor bindings). After an evening of drinking, GABA dominates the first half of the night of sleep, allowing the drinker to fall into a deep sleep. However, once GABA is metabolized, much of it becomes glutamate. When glutamate is released in certain regions of the brain, such as the reticular activating system, which partially regulates sleep, wake, and arousal, the drinker's sleep pattern is disrupted. This causes the consumer to wake. This cycle is referred to as the “rebound effect.”
- Various forms of “hangover cures” are utilized throughout the drinking population. For example, nonsteroidal anti-inflammatory drugs (“NSAIDs”) such as aspirin and ibuprofen are used. NSAIDs are generally effective at relieving headaches and muscle aches. However, NSAIDs also cause intestinal irritability while not addressing other hangover symptoms including certain inflammation caused by alcohol consumption that cannot be treated with nSAIDs
- Vitamins are also used to combat hangover symptoms. Alcohol depletes some water-soluble vitamins, especially B complex vitamins. However, vitamin supplementation after the onset of a hangover will have little to no effect on the hangover following acute alcohol consumption. Moreover, there is little to no evidence that vitamin supplements alone improve acute hangover symptoms.
- The amino acid, N-acetylcysteine or N-Acetyl L-Cysteine (“NAC”), is used to boost the production of the antioxidant glutathione and support more efficient alcohol metabolism while reducing oxidative damage to the body. It has been studied as a protective agent, rather than a hangover treatment. The results of some animal studies suggest that NAC may decrease ethanol induced hypertension and acetaldehyde levels in rats, but there is little evidence to support NAC's efficacy as a treatment for hangovers in human subjects.
- Some people also use caffeine to treat hangovers. Caffeine is a commonly used stimulant to combat the lethargy and headaches associated with hangovers. However, many caffeinated drinks such as coffee are diuretics and can exacerbate the dehydration associated with the hangover.
- Another common hangover remedy is to drink more alcohol to ease the symptoms—sometimes referred to as “taking the hair of the dog” or “hair of the dog that bit you.” The notion here is that hangovers are a form of alcohol withdrawal and drinking more alcohol will ease the withdrawal. However, this perpetuates the cycle of drinking, ultimately prolonging the hangover, and can lead to addiction.
- One attempt to cure hangovers is U.S. Pat. No. 9,603,830 to Powell. However, this reference only discloses a treatment in a pill form and does not address many sources of symptoms associated with hangovers. For example, Powell does not attempt to redress the inflammation and allergic reactions associated with hangovers.
- Another attempt to cure hangover is U.S. Pat. No. 6,485,758 to Mirza, et al. However, this reference does not address many sources of symptoms associated with hangovers. For example, like Powell, Mirza does not attempt to redress the inflammation or certain allergic reactions associated with hangovers.
- A common problem to most currently available hangover remedies is that the antidotes are applied typically when the hangover symptoms have already commenced, i.e. the critical period to prevent and/or treat adverse symptoms have progressed too long to be efficacious. Further, most commercially-available hangover remedies fail to address inflammation effects of alcohol toxicity by specifically using anti-inflammatory agents. Typically, hangover symptoms peak when the blood alcohol content (“BAC”) is near or at zero. Therefore, what is needed is a hangover treatment that contains compositions that mitigate symptoms associated with veisalgia and that enable the body to prevent a hangover from setting in. This need has heretofore remained unsatisfied.
- The present invention overcomes these and other deficiencies of the prior art by providing a composition for veisalgia treatment that mitigates and prevents its symptoms.
- In an embodiment of the invention, a composition stimulates enzymes associated with metabolizing alcohol and/or acetaldehyde—both toxic substances—into acetate—a non-toxic substance. In some embodiments, the composition is directed to stimulating alcohol dehydrogenases (“ADH”)— a group of dehydrogenase enzymes that occur in many organisms and facilitate the interconversion between alcohols and aldehydes or ketones with the reduction of nicotinamide adenine dinucleotide (“NAD”) to NADH. ADH serves to break down alcohols that otherwise are toxic, and they also participate in generation of useful aldehyde, ketone, or alcohol groups during biosynthesis of various metabolites.
- In another embodiment, the present invention stimulates the body's production of aldehyde dehydrogenases (“ALDH”)—a group of enzymes that catalyze the oxidation of aldehydes. ALDH converts aldehydes to carboxylic acids.
- In an exemplary embodiment of the present invention, a composition for treating symptoms associated with veisalgia comprises dihydromyricetin, N-acetyl cysteine, and salicin. In some embodiments, the composition further comprises at least one of the ingredients selected from the group consisting of: quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, turmeric, curcumin, milk thistle, monk fruit, hydroxypropyl-beta cyclodextrin, ginger root, and black pepper extract. In some embodiments, the composition is integrated into a liquid. In some embodiments, the composition is integrated into a capsule, tablet, chewable tablet, or pill. In some embodiments, the composition is a powder or liquid form and is readily integratable into food or drink.
- In another exemplary embodiment of the present invention, a method for treating symptoms associated with veisalgia comprises administering, to a patient, a composition comprising dihydromyricetin, N-acetyl cysteine, and salicin. In some embodiments, the composition further comprises quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, turmeric, curcumin, milk thistle, monk fruit, hydroxypropyl-beta cyclodextrin, ginger root, or black pepper extract, or a combination thereof. In some embodiments, the composition is administered as a liquid. In some embodiments, the composition is administered as a capsule, tablet, chewable tablet, or pill. In some embodiments, the composition is administered via food or drink. In some embodiments, the composition is administered by injection intravenously, intramuscularly, intrathecally, or subcutaneously; sublingually or buccally; rectally or vaginally; placed in the eye by the ocular route or the ear by the otic route; nasally; inhalation or by nebulization; applied to the skin cutaneous for a local topical or body wide systemic effect; or delivered through the skin by patch transdermally for systemic effect.
- The foregoing, and other features and advantages of the invention, will be apparent from the following, more particular description of the preferred embodiments of the invention, the accompanying drawings, and the claims.
- For a more complete understanding of the present invention, the objects and advantages thereof, reference is now made to the ensuing descriptions taken in connection with the accompanying drawings briefly described as follows:
-
FIG. 1 illustrates a table of exemplary amounts of ingredients, all various subsets of which are found in one or more embodiments of the present invention; and -
FIG. 2 illustrates exemplary methods of administering a composition for treating veisalgia. - Preferred embodiments of the present invention and their advantages may be understood by referring to
FIGS. 1-2 . Further features and advantages of the invention, as well as the structure and operation of various embodiments of the invention, are described in detail below. Although the invention is described in the context of a compound, any form may be implemented such as, but not limited to a powder, a pill, or a liquid, or other form suitable for various administrations, including as a nutritional supplement to treat other maladies such as headaches, dehydration, fatigue, and sensitivity to light and sound. - Reference throughout this specification to “one embodiment,” “an embodiment,” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.
- Moreover, the described features, structures, or characteristics of the invention may be combined in any suitable manner in one or more embodiments. It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents. Reference will now be made in detail to the preferred embodiments of the invention.
- In an exemplary embodiment of the present invention and with reference to
FIG. 1 , a composition for veisalgia treatment comprises dihydromyricetin (“DHM”). DHM is used as an alcohol metabolism accelerator. DHM may be found naturally in the Japanese raisin tree (Hovenia dulcis) and has been used in Chinese herbal tea. DHM may also be referred to as ampelopsin and found in vine tea extract. DHM accelerates alcohol metabolism but it can also prevent alcohol from affecting the brain's GABA receptors, thereby mitigating or preventing the rebound effect. The composition for veisalgia treatment may further comprise Salicin. Salicin is commonly found in Willow Bark and may be utilized in various concentrations. For example, some embodiments comprise Willow Bark having 15% to 98% concentration of salicin. Salicin is an alcoholic beta-glucoside and is produced in willow (salix) bark and has anti-inflammatory properties. Salicin is also commonly found in the bark of populus species, and the leaves of willows and poplars. It may also be found in castoreum, which may be used as an analgesic, anti-inflammatory, and antipyretic. The composition for veisalgia treatment may further comprise NAC. - In another exemplary embodiment of the present invention, a composition for veisalgia treatment may further comprise quercetin—a chemical found naturally in a number of foods and in some herbs. It acts as an antioxidant and also possesses anti-inflammatory and antihistamine properties, which reduces inflammation and allergic reactions triggered by alcohol. Other embodiments include bromelain, which supports normal mucosal tissue function and enhances the absorption of quercetin. Some embodiments include a combination of quercetin and bromelain, while other embodiments may include the combination of quercetin and bromelain in leu of salicin.
- In another exemplary embodiment of the present invention, a composition for treating veisalgia mitigates adverse alcohol effects in the body by accelerating alcohol metabolism in the liver and supporting the immune system.
- In another exemplary embodiment of the present invention, a composition for treating veisalgia functions as an alcohol metabolism accelerator and as a natural anti-inflammatory. The dual benefit contributes to positive effects on headache and fatigue post-alcohol overconsumption.
- In another exemplary embodiment of the present invention, a composition for treating veisalgia comprises at least one anti-inflammatory agent that attenuates headaches or muscle aches associated with veisalgia.
- In another exemplary embodiment of the present invention, the at least one anti-inflammatory agent is one selected form a group including: salicin (willow bark), Quercetin, Bromelain, or a combination thereof.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment comprises an extract of Opuntia ficus-indica. Opuntia ficus-indica is commonly referred to as prickly pear and is a genus in the cactus family, Cactaceae. Various forms of Opuntia (or prickly pear) may be used. For example, some embodiments of the present invention comprise the extract Tex-OE® which includes special active molecules derived from the skin of the fruit of the Prickly Pear. Some embodiments include cactus extract at a concentration of 4:1.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment comprises caffeine.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment comprises turmeric. Some embodiments comprise turmeric root extract. Other embodiments comprise curcumin extract. Curcumin is a natural anti-inflammatory and many of the adverse effects of alcohol hangovers are due to inflammation. In an exemplary embodiment of the invention, a composition for veisalgia treatment comprises approximately 200 mg to 1000 mg of curcumin and/or turmeric. Some embodiments include turmeric comprising approximately 10% curcumin.
- In another exemplary embodiment, a composition for veisalgia treatment comprises Monk Fruit, which has anti-inflammatory properties and is safe for diabetes in that there are no calories, carbs, sugar, or fat. In an exemplary embodiment of the invention, a composition for veisalgia treatment comprises approximately 5 mg to 200 mg of Monk Fruit. Some embodiments include
Monk Fruit MV 50%. - In another exemplary embodiment of the present invention, a composition for veisalgia treatment comprises Milk Thistle, which supports liver health. In an exemplary embodiment of the invention, a composition for veisalgia treatment comprises approximately 5 mg to 200 mg of Milk Thistle. Some embodiments include Milk Thistle comprising approximately 80% silymarin.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment comprises hydroxypropyl-beta cyclodextrin (“HPBCD”), a highly soluble substance which can be used to increase the solubility of the ingredients. HPBCD may be used, for example, in integrating the composition for veisalgia treatment into a liquid form. Additionally, HPBCD may be used to enhance the absorption rate of the composition for treating veisalgia. In an exemplary embodiment of the invention, a composition for veisalgia treatment comprises approximately 3 g to 8 g of HPBCD.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment comprises ginger. Some embodiments comprise ginger root extract while others comprise powdered ginger.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment comprises taurine. Other embodiments comprise black pepper extract.
- In another exemplary embodiment, a composition for veisalgia treatment comprises potassium, sodium, and/or magnesium, either individually or in combination. Alcohol, like any diuretic, depletes the body of potassium and salts. In such and embodiment, these minerals in this composition is necessary for body rehydration and proper nerve and muscle functions. Moreover, magnesium may support the alcohol dehydrogenase (“ADH”), an enzyme in accelerating the alcohol break down and eliminating it from the body. Some embodiments include magnesium comprising approximately 60% oxide.
- In another exemplary embodiment, a composition for veisalgia treatment comprises various B vitamins, including but not limited to, thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), biotin (B7), folic acid, vitamin B6, and/or vitamin B12. Some embodiments comprise thiamine HCL, riboflavin 5-phosphate, and/or pyridoxine HCL.
- In another exemplary embodiment, a composition for veisalgia treatment comprises vitamin C. Some embodiments include vitamin C comprising calcium ascorbate.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment is a compound comprising a combination of DHM, willow bark (salicin), N-acetyl cysteine (“NAC”), opuntia (nopal cactus), quercetin, and/or bromelain.
- In another exemplary embodiment of the present invention, a composition for veisalgia treatment is a beverage comprising DHM, willow bark, NAC, opuntia, a combination of B vitamins, potassium, sodium, magnesium, quercetin, and/or bromelain.
- The table depicted in
FIG. 1 illustrates some of the ingredients of the present invention, along with exemplary amounts for each. Notably, the table is not offered as an exhaustive or exclusive list but rather as exemplary ingredients. Moreover, the ingredients may be used by themselves, in combination with some or all of the other ingredients listed, or with other ingredients not listed, without departing from the embodiments contemplated herein. Further, the ingredients listed may be incorporated in various concentrations. For example, willow bark includes salicin in varying concentrations. Willow bark may have salicin concentrations of anywhere between approximately 15% to approximately 98%—the entire range of which may be used in amount varying between approximately 40 mg to approximately 180 mg. Additionally, the ingredients listed may be utilized in treatments for veisalgia outside of the amounts shown without departing from the embodiments contemplated herein. In addition to the exemplary ingredients disclosed, other ingredients may be used to assist administration. In one embodiment, HPBCD is used to make a homogenous liquid by improving the water solubility of the ingredients. For example, in an embodiment where the veisalgia treatment is integrated into a drinkable liquid, the veisalgia treatment may further include natural and/or artificial flavorings or colors. In one embodiment, the natural flavorings include monk fruit. In another example where the veisalgia treatment is integrated into a capsule or tablet, the veisalgia treatment may also include binding agents or other inactive ingredients. - In another exemplary embodiment of the present invention and with reference to
FIG. 2 , a composition forveisalgia treatment 200 may be administered in a variety of ways atstep 210. Theveisalgia treatment 200 comprises composition according to the embodiments described above. Theveisalgia treatment 200 may be administered by injection including intravenously, intramuscularly, intrathecally, or subcutaneously. In another embodiment, as shown atstep 230, theveisalgia treatment 200 may be administered sublingually or buccally. In another embodiment, as shown atstep 240, theveisalgia treatment 200 may be administered rectally or vaginally. In another embodiment, as shown atstep 250, theveisalgia treatment 200 may be administered ocularly (through the eye) or oticly (through the ear). In another embodiment, as shown atstep 260, theveisalgia treatment 200 may be administered nasally by, for example, through inhalation or by nebulization. In another embodiment, as shown atstep 270, theveisalgia treatment 200 may be administered topically or transdermally, for example by patch. - Although the present invention may discuss a composition for veisalgia treatment in the form of a compound, other forms may be utilized without departing from the embodiments contemplated herein. For example, the present invention may be administered orally. In such an embodiment, the veisalgia treatment may be integrated into a liquid, capsule, tablet, chewable tablet, or pill. In such an embodiment, a liquid veisalgia treatment may be prepared by first combining HPBCD, DHM, Salicin, NAC, and Turmeric (as exemplary ingredients). Next, the remaining ingredients (such as flavoring compounds), if any, may be separately combined. The two mixtures may then be combined to finalize the liquid veisalgia treatment.
- Some embodiments further include flavorings. For example, various embodiments comprise natural flavorings including lemon and lime flavorings. Other embodiments may include citric acid and/or malic acid.
- In other embodiments, a composition for veisalgia treatment may be integrated into food by, for example, being included in the food's preparation, e.g., added as an ingredient into a food such as candy/protein/power bar or mixed in yogurt, or may be integrated into food in the way many condiments are, e.g., a powder or liquid form that is sprinkled on or added into food much like salt, pepper, ketchup, or mustard. In other embodiments, the veisalgia treatment may be integrated into the drinker's alcoholic beverage, either being mixed into the alcohol itself or added by the consumer/preparer of the beverage. An advantage to this embodiment is the drinker may ensure the veisalgia treatment is indeed administered and/or administered in the proper amount.
- The present invention may also be administered to a patient in other ways without departing from the embodiments contemplated herein including: given by injection into a vein (intravenously, IV), into a muscle (intramuscularly, IM), into the space around the spinal cord (intrathecally), or beneath the skin (subcutaneously, SC); placed under the tongue (sublingually) or between the gums and cheek (buccally); inserted in the rectum (rectally) or vagina (vaginally); placed in the eye (by the ocular route) or the ear (by the otic route); sprayed into the nose and absorbed through the nasal membranes (nasally); breathed into the lungs, usually through the mouth (by inhalation) or mouth and nose (by nebulization); applied to the skin (cutaneously) for a local (topical) or bodywide (systemic) effect; and/or delivered through the skin by patch (transdermally) for systemic effect.
- Although the present invention is described herein as a composition for treating veisalgia, the invention may be used to treat other maladies, including, for example, dehydration, nausea, fatigue, headache, light and sound sensitivity, and dizziness. The present invention may also be used to treat patients with migraine headaches. Migraine patients reported that the presently described veisalgia treatment helped them (on more than one occasion) to cope with alcohol-triggered migraines. After taking the presently described veisalgia treatment, patients reported a “surprisingly positive” experience of waking up with no migraine or headache triggered by alcohol overconsumption. Additionally, although the present invention is shown and described as comprising various specific ingredients, the present invention may include all subsets of disclosed ingredients, without departing from the embodiments contemplated herein.
- The composition for treatment of veisalgia may be administered in capsule form. In such an embodiment, the ingredients are mixed together until homogenous. Various types of encapsulation may be utilized, for example, single-piece gel encapsulation (soft capsules) and two-piece gel encapsulation (hard capsules). The ingredients may be suspended in a liquid (such as oil) and placed inside of the capsule. Alternatively, the composition for treatment of veisalgia may be offered in liquid form. In such an embodiment, the specified ingredients may be homogenously mixed together and dissolved in a medium.
- The invention has been described herein using specific embodiments for the purposes of illustration only. It will be readily apparent to one of ordinary skill in the art, however, that the principles of the invention can be embodied in other ways. Therefore, the invention should not be regarded as being limited in scope to the specific embodiments disclosed herein, but instead as being fully commensurate in scope with the following claims.
Claims (11)
1. A composition comprising dihydromyricetin, N-acetyl cysteine, and salicin.
2. The composition of claim 1 further comprising at least one of the ingredients selected from the group consisting of: quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, turmeric, curcumin, milk thistle, monk fruit, hydroxypropyl-beta cyclodextrin, ginger root, and black pepper extract.
3. The composition of claim 1 , wherein the composition is integrated into a liquid.
4. The composition of claim 1 , wherein the composition is integrated into a capsule, tablet, chewable tablet, or pill.
5. The composition of claim 1 , wherein the composition is in powder or liquid form and is readily integratable into food or drink.
6. A method for treating symptoms associated with veisalgia comprising:
administering, to a patient, a composition comprising dihydromyricetin, N-acetyl cysteine, and salicin.
7. The method of claim 6 , wherein the composition further comprises quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, turmeric, curcumin, milk thistle, monk fruit, hydroxypropyl-beta cyclodextrin, ginger root, or black pepper extract, or a combination thereof.
8. The method of claim 6 , wherein the composition is integrated into a liquid.
9. The method of claim 6 , wherein the composition is integrated into a capsule, tablet, chewable tablet, or pill.
10. The method of claim 6 , wherein the composition is administered via food or drink.
11. The method of claim 6 , wherein the composition is administered by injection intravenously, intramuscularly, intrathecally, or subcutaneously; sublingually or buccally; rectally or vaginally; placed in the eye by the ocular route or the ear by the otic route; nasally; inhalation or by nebulization; applied to the skin cutaneous for a local topical or body wide systemic effect; or delivered through the skin by patch transdermally.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/977,969 US20230051702A1 (en) | 2019-02-22 | 2022-10-31 | Compositions for prevention and treatment of symptoms associated with alcohol consumption |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962809497P | 2019-02-22 | 2019-02-22 | |
US16/799,792 US11484523B1 (en) | 2019-02-22 | 2020-02-24 | Compositions for prevention and treatment of symptoms associated with alcohol consumption |
US17/977,969 US20230051702A1 (en) | 2019-02-22 | 2022-10-31 | Compositions for prevention and treatment of symptoms associated with alcohol consumption |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/799,792 Continuation US11484523B1 (en) | 2019-02-22 | 2020-02-24 | Compositions for prevention and treatment of symptoms associated with alcohol consumption |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230051702A1 true US20230051702A1 (en) | 2023-02-16 |
Family
ID=83809424
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/799,792 Active 2040-11-06 US11484523B1 (en) | 2019-02-22 | 2020-02-24 | Compositions for prevention and treatment of symptoms associated with alcohol consumption |
US17/977,969 Pending US20230051702A1 (en) | 2019-02-22 | 2022-10-31 | Compositions for prevention and treatment of symptoms associated with alcohol consumption |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/799,792 Active 2040-11-06 US11484523B1 (en) | 2019-02-22 | 2020-02-24 | Compositions for prevention and treatment of symptoms associated with alcohol consumption |
Country Status (1)
Country | Link |
---|---|
US (2) | US11484523B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240058411A1 (en) * | 2022-08-22 | 2024-02-22 | Owen Garratt | Composition for treating and/or preventing a hangover |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080075710A1 (en) * | 2006-09-25 | 2008-03-27 | Liquid Potions Llc | Herbal composition for treating hangovers |
US9603830B2 (en) * | 2014-05-29 | 2017-03-28 | Thriveplus Llc | Compositions and methods for preventing and recovery from detrimental effects of alcohol consumption |
-
2020
- 2020-02-24 US US16/799,792 patent/US11484523B1/en active Active
-
2022
- 2022-10-31 US US17/977,969 patent/US20230051702A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11484523B1 (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tam et al. | Yohimbine: a clinical review | |
US6159505A (en) | Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine | |
US20050276839A1 (en) | Appetite satiation and hydration beverage | |
US10028991B2 (en) | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication | |
WO1999051252A1 (en) | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation | |
US20050008726A1 (en) | Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
WO2012027603A2 (en) | Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2 | |
JPS63313726A (en) | Method and composition for treating nervous disease such as hemicrania by stimulating nervous cell | |
US6827932B2 (en) | Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages | |
US20230051702A1 (en) | Compositions for prevention and treatment of symptoms associated with alcohol consumption | |
US6913769B2 (en) | Compositions for prevention and treatment of symptoms associated with ethyl alcohol consumption | |
GB2368012A (en) | Preparation for the relief of inflammatory disease | |
US20100021570A1 (en) | Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke | |
Houston | Treatment of hypertension with nutrition and nutraceutical supplements: Part 2 | |
US20040137081A1 (en) | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins | |
BE1023090B1 (en) | COMPOSITION | |
RU2327482C1 (en) | Composition and method of treatment of postintoxicational state and alcoholic abstinence syndrome-hangover (versions) | |
RU2393721C2 (en) | Agent and alcohol-free drink for prophylactics of consequences and reduction of manifestations of acute alcohol intoxication | |
BE1026122B1 (en) | Composition for preventing or reducing the effects of alcohol poisoning | |
US20050171030A1 (en) | Relieving symptoms of erectile dysfunction and attaining sexual wellness and health of the sexual vascular system with proanthocyanidins | |
US20230270711A1 (en) | Improved Anti-Hangover Composition, Its Preparation and Uses | |
AU2004204527B2 (en) | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins | |
EP3071197B1 (en) | Food for special medical purposes or food supplement formulation for treating hearing disturbances | |
RU2146529C1 (en) | Kit of antialcoholic agents | |
EP3357541B1 (en) | Methylsulfonylmethane composition for reducing blood alcohol content |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |